Assistant Professor, Internal Medicine, Mayo Medical School
Hematology
Dr. Animesh D. Pardanani, MD
|
|
Give Review
Animesh D. Pardanani, MD works in the field of Hematology. Animesh Pardanani is a published doctor and has 56 publications published. The lastest was: 'Calreticulin (CALR) variant stratified driver mutational status and prognosis in essential thrombocythemia.' Animesh Pardanani accepts Medicare payments and is listed with Medicare.gov.
Publications
- Targeted next generation sequencing of PDGFRB rearranged Myeloid neoplasms with monocytosis.
- Next generation sequencing of Myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
- Calreticulin (CALR) variant stratified driver mutational status and prognosis in essential thrombocythemia.
- Targeting megakaryocytic-induced fibrosis in Myeloproliferative neoplasms by AURKA inhibition.
- Chronic neutrophilic Leukemia: novel mutations and their impact on clinical practice.
- Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic Mast cells.
- Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.
- Is there a role for JAK inhibitors in BCR-ABL1-negative Myeloproliferative neoplasms other than myelofibrosis?
- A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients.
- Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.
- Thymoma-associated Pancytopenia: immunosuppressive therapy is the cornerstone for durable hematological remission.
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
- Mutations and Thrombosis in essential thrombocythemia: prognostic interaction with age and Thrombosis history.
- Calreticulin mutations and long-term survival in essential thrombocythemia.
- Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients.
- CALR mutation studies in chronic neutrophilic Leukemia.
- Altered expression of tumor suppressor PHF20 in Myeloproliferative neoplasms.
- Genetics: CALR mutations and a new diagnostic algorithm for MPN.
- Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
- Drug-drug interaction between bosutinib and warfarin.
- Chronic neutrophilic Leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment...
- U2AF1 mutations in primary myelofibrosis are strongly associated with Anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype.
- Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing.
- Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic Syndromes.
- Mayo prognostic model for WHO-defined chronic myelomonocytic Leukemia: ASXL1 and spliceosome component mutations and outcomes.
- Clonal Mast cell disease not meeting WHO criteria for diagnosis of Mastocytosis: clinicopathologic features and comparison with indolent Mastocytosis.
- AKT is a therapeutic target in Myeloproliferative neoplasms.
- Survival and prognosis among 1545 patients with contemporary Polycythemia vera: an international study.
- CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic Leukemia.
- SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic Leukemia (CMML): independent prognostic impact in CMML.
- Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.
- How I treat patients with indolent and smoldering Mastocytosis (rare conditions but difficult to manage).
- Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of Myeloproliferative neoplasms.
- International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response crite...
- Increased circulating IL-2R? (CD25) predicts poor outcome in both indolent and aggressive forms of Mastocytosis: a comprehensive cytokine-phenotype study.
- Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic Leukemia: Prevalence, clinical correlates, and prognostic relevance.
- Systemic Mastocytosis: disease overview, pathogenesis, and treatment.
- Lymphoma-associated versus lymphocytic-variant hypereosinophilia.
- Sole abnormalities of chromosome 7 in Myeloid malignancies: Spectrum, histopathologic correlates, and prognostic implications.
- Treatment-refractory idiopathic hypereosinophilic Syndrome: Pitfalls and progress with use of novel drugs.
- Plasma cytokines in Polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis.
- Systemic Mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
- Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: Performance in 87 myelofibrosis patients on a JAK1 and JA...
- Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
- Phase1/-2 study of Pomalidomide in myelofibrosis.
- International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using Cell lines and primary Cells from polycythemia vera pa...
- TET2 mutations and their clinical correlates in Polycythemia vera, essential thrombocythemia and myelofibrosis.
- Frequent TET2 mutations in systemic Mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.
- MPL515 mutations in myeloproliferative and other Myeloid disorders: a study of 1182 patients.
- Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic Leukemia.
- Definition and management of ruxolitinib treatment failure in myelofibrosis.
- Chronic Eosinophilic Leukemia-Not Otherwise Specified (NOS) in the Background of a Large Cell Lymphoma.
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
St Luke's-Roosevelt Hospital Center
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1700856804 | |
| NPPES Provider LastName | PARDANANI | |
| NPPES Provider FirstName | ANIMESH | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 83.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1700856804 |
| Last Name Of The Provider | PARDANANI |
| First Name Of The Provider | ANIMESH |
| View All |
Similar Doctors
|
|
Dr. Suzanne R. Hayman, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Robert L. Foote, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Mark R. Litzow, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Randolph S. Marks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick A. Burch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen Frytak, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Andrew L. Feldman, MD |
|
|
Dr. Shaji K. Kumar, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Phuong L. Nguyen, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Robert L. Phyliky, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Carrie A. Thompson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martha Q. Lacy, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Wilson I. Gonsalves, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aneel A. Ashrani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brandt L. Esplin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dennis A. Gastineau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lynn C. Hartmann, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Richard J. Bram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Humeniuk, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Minetta Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Carrie M. Thompson, NP
This Doctor is OpenDoctor Recommended.
|